Hesamizadeh Khashayar, Tavakoli Ahmad, Nikbin Mehri
Middle East Liver Disease (MELD) Center, Tehran, Iran.
Department of Medical Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Med J Islam Repub Iran. 2019 Jul 1;33:63. doi: 10.34171/mjiri.33.63. eCollection 2019.
Hepatitis C virus (HCV) infection is a cause of major liver complications, particularly in patients infected with human immunodeficiency virus (HIV). This study aimed to evaluate the efficacy of pegylated interferon (Peg-IFN) and a fixed dose of ribavirin treatment among Iranian HCV mono-infected and HCV/HIV-co-infected patients. A total of 214 HCV mono-infected and HCV/HIV co-infected patients attending Liver Disease Center in Tehran were assigned to receive treatment with Peg-IFN-α2a or -α2b plus ribavirin for 24-48 weeks. Sustained virologic response (SVR) was used as the primary efficacy endpoint of Peg-IFN and ribavirin therapy. Treatment with Peg-IFN and ribavirin has been associated with a considerably higher rate of SVR (24 weeks for HCV genotype 3 and 48 weeks for HCV/HIV co-infected and HCV genotype 1 patients). Overall, the clearance of HCV-RNA at the end of therapy occurred in 48.6% of patients. Adverse events leading to treatment discontinuation were seen in 14% of patients. This retrospective study revealed a relatively well-tolerated response in both HCV mono-infected and HCV/HIV coinfected patients during treatment with Peg-IFN and ribavirin. However, the recent revolutionized interferon-free therapies for chronic HCV infection should be taken into account for achieving a greater response and minimal adverse events.
丙型肝炎病毒（HCV）感染是主要肝脏并发症的一个病因，尤其在感染人类免疫缺陷病毒（HIV）的患者中。本研究旨在评估聚乙二醇化干扰素（Peg-IFN）和固定剂量利巴韦林治疗在伊朗HCV单感染和HCV/HIV合并感染患者中的疗效。共有214例就诊于德黑兰肝病中心的HCV单感染和HCV/HIV合并感染患者被分配接受Peg-IFN-α2a或-α2b加利巴韦林治疗24至48周。持续病毒学应答（SVR）被用作Peg-IFN和利巴韦林治疗的主要疗效终点。Peg-IFN和利巴韦林治疗与相当高的SVR率相关（HCV基因3型为24周，HCV/HIV合并感染和HCV基因1型患者为48周）。总体而言，48.6%的患者在治疗结束时实现了HCV-RNA清除。14%的患者出现了导致治疗中断的不良事件。这项回顾性研究表明，在Peg-IFN和利巴韦林治疗期间，HCV单感染和HCV/HIV合并感染患者的反应耐受性相对良好。然而，为了获得更好的反应和最小的不良事件，应考虑到最近针对慢性HCV感染的无干扰素疗法的变革。
